Holen Sie sich die Stockscreener-App
35.24
1.73%
-0.62
Handel nachbörslich:
35.24
Schlusskurs vom Vortag:
$35.86
Offen:
$35.86
24-Stunden-Volumen:
604.68K
Relative Volume:
0.74
Marktkapitalisierung:
$2.04B
Einnahmen:
$899.11M
Nettoeinkommen (Verlust:
$145.62M
KGV:
14.19
EPS:
2.4829
Netto-Cashflow:
$322.54M
1W Leistung:
-0.23%
1M Leistung:
-3.21%
6M Leistung:
-3.50%
1J Leistung:
+0.17%
1-Tages-Spanne:
$34.58
$35.87
1-Wochen-Bereich:
$34.58
$37.08
52-Wochen-Spanne:
$25.52
$40.87
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
35.24 | 2.08B | 899.11M | 145.62M | 322.54M | 2.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-23 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-02-23 | Herabstufung | Truist | Buy → Hold |
| 2026-02-11 | Fortgesetzt | UBS | Neutral |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-10 | Eingeleitet | UBS | Buy |
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
Harmony Biosciences: WAKIX Cash Flow Funds Its Own Disruption (NASDAQ:HRMY) - Seeking Alpha
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Yahoo Finance
Harmony Biosciences Holdings Inc (HRMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Income Statement - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Harmony Biosciences Holdings Inc - TradingKey
Zacks Value Investor Highlights: HRMY, NVDA and VLO - TradingView
Did CFO Exit and Reaffirmed 2026 Guidance Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st
HRMY|Harmony Biosciences Holdings Inc|Price:35.320|Chg%:-0.480 - TradingKey
HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - Stocktwits
Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreement - Stocktwits
How Many Stocks Should You Own? - TradingView
Harmony Biosciences Holdings Inc (HRMY) Institutional Confidence - TradingKey
ETFs Investing in Harmony Biosciences Holdings, Inc. Stocks - TradingView
Harmony Biosciences (HRMY) Says Goodbye To Its CFO And Names An Interim Finance Chief - Yahoo Finance
Harmony Biosciences interim principal financial officer Stephen Mollichella files initial beneficial ownership statement - Bitget
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo! Finance Canada
Harmony Biosciences (HRMY) officer details stock and option holdings - Stock Titan
Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo! Finance Canada
Harmony Biosciences Holdings Jumps 9.6% Amid Sector-Wide Rally - AlphaStreet
Harmony Biosciences to report Q2 2026 results on August 4 - scanx.trade
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 - The Manila Times
Harmony Biosciences will host a live Q2 results webcast on Aug. 4 - Stock Titan
H.C. Wainwright reiterates Harmony Biosciences stock rating on demand beat - Investing.com UK
H.C. Wainwright reiterates Harmony Biosciences stock rating on demand beat By Investing.com - Investing.com Nigeria
Harmony Bio drops after CFO exit - MSN
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Biosciences announces preliminary Q2 revenue, CFO transition — says executive’s departure not due to any disagreement - MSN
Understanding the Setup: (HRMY) and Scalable Risk - Stock Traders Daily
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition - Yahoo Finance
H.C. Wainwright reiterates Harmony Biosciences stock rating on strong Q2 results - Investing.com Nigeria
H.C. Wainwright reiterates Harmony Biosciences stock rating on strong Q2 results By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Harmony Biosciences Posts Record Q2 WAKIX Revenue - TipRanks
HRMY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $55 - GuruFocus
Harmony Biosciences CFO Reicin steps down, names Mollichella interim finance chief - Bitget
Harmony Biosciences reaffirms 2026 net revenue outlook of $1 billion-$1.04 billion - Bitget
Harmony Biosciences CFO Glenn Reicin Resigns - Moomoo
Harmony Biosciences (HRMY) CFO Resigns Amid Record Wakix Sales - GuruFocus
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition - Investing News Network
Harmony (HRMY) Maintains 2026 Revenue Forecast - GuruFocus
Harmony Bio stock drops after CFO exit (HRMY:NASDAQ) - Seeking Alpha
Harmony Biosciences reports record Q2 WAKIX sales of $261M - scanx.trade
Harmony (HRMY) Announces CFO Departure and Interim Appointment - GuruFocus
Harmony Biosciences Holdings, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):